When compared to another weight-loss drug (liraglutide), semaglutide helps people lose nearly twice as much weight—over 70% lose 10% or more of their body weight, while only about 1 in 4 do with liraglutide.
Claim Context
Among adults with obesity without diabetes, semaglutide 2.4 mg results in greater weight loss than liraglutide 3.0 mg, with mean differences of 9.4% at 68 weeks and higher rates of achieving ≥10% weight loss (70.9% vs. 25.6%).
“STEP 8: -15.8% with semaglutide vs. -6.4% with liraglutide (difference: -9.4% [95% CI: -12 to -6.8]; p<.001)... 70.9% of patients treated with semaglutide achieved ≥10% body weight loss vs. 25.6% with liraglutide (p<.001).”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The pooled comparative efficacy of semaglutide 2.4 mg versus liraglutide 3.0 mg across all available RCTs for weight loss, including subgroup analyses by BMI, sex, and comorbidities.
A systematic review and meta-analysis of all head-to-head RCTs comparing semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily in adults with BMI ≥30 kg/m², with primary outcome: percent weight change at 68–104 weeks, using intention-to-treat analysis and standardized outcome definitions.
Causal superiority of semaglutide 2.4 mg over liraglutide 3.0 mg for weight loss.
A double-blind, double-dummy RCT of 500+ adults with BMI ≥30 kg/m² and no diabetes, randomized to semaglutide 2.4 mg weekly or liraglutide 3.0 mg daily, both with standardized lifestyle counseling, measuring percent weight change, waist circumference, and quality of life at 68 weeks.
Real-world comparative effectiveness and persistence of semaglutide 2.4 mg versus liraglutide 3.0 mg in routine clinical care.
A prospective cohort study of 3000+ patients prescribed semaglutide 2.4 mg or liraglutide 3.0 mg in primary care or endocrinology clinics, matched by BMI, age, and comorbidities, tracking weight change, discontinuation, and adverse events over 3 years.
Association between semaglutide 2.4 mg use and rare adverse events (e.g., gallbladder disease) compared to liraglutide 3.0 mg.
A case-control study comparing 400 patients with confirmed gallbladder disease requiring intervention within 12 months of starting semaglutide or liraglutide to 1600 matched controls without such events, assessing drug exposure, duration, and dose.
Expert consensus on which drug to prefer first-line for weight loss in specific patient subgroups.
A Delphi consensus process among 25+ obesity specialists evaluating efficacy, safety, cost, and adherence data to rank semaglutide 2.4 mg and liraglutide 3.0 mg for different patient profiles (e.g., with vs. without diabetes, high vs. low BMI).